Trade. Its trading at current pps because their r no catalysts to drive pps higher at the moment.
The science is sound at least so far for phase 1 and 2a. But like any biotech. We all know those who show promising data early on can fail in expanded efficacy trials
That said i still do belief they have the most promising hiv vaccine in efficacy trial Lack of funding, internal politics at nih seem to be holding things up.
Its weird how all of a sudden they dropped govxb21 and hvtn forcing them to go with a protein boost
News 
Market Data 
Discover 
